Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsMIL:1HALO +0.70%75 Cyclically Adjusted PS Ratio is 17.54 as of Aug. 06, 2026, which is 20% below its 10-year median of 21.94. GuruFocus rates MIL:1HALO with a GF Score™ of 75/100 and a GF Value™ of €79.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 537 Biotechnology companies, Halozyme Therapeutics ranks worse than 78.96% on this metric.
The historical rank and industry rank for Halozyme Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
MIL:1HALO'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 13 Med: 21.94 Max: 44.11
Current: 17.41
During the past years, Halozyme Therapeutics's highest Cyclically Adjusted PS Ratio was 44.11. The lowest was 13.00. And the median was 21.94.
MIL:1HALO's Cyclically Adjusted PS Ratio is ranked worse than 78.96% of 537
companies
in the Biotechnology industry
Industry Median: 5.5
vs MIL:1HALO: 17.41
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Halozyme Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2026 was €2.652. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €4.10 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Halozyme Therapeutics (MIL:1HALO) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Halozyme Therapeutics Cyclically Adjusted PS Ratio Related Terms
Halozyme Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Cyclically Adjusted PS Ratio Chart
MIL:1HALO vs NUVL, KRYS, IONS: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PS Ratio falls into.
Halozyme Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 17.54 mean?
Halozyme Therapeutics (MIL:1HALO) has a Cyclically Adjusted PS Ratio of 17.54 as of Aug. 06, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors. This is 20% below median its historical median of 21.94. Over the past decade, Halozyme Therapeutics' Cyclically Adjusted PS Ratio has ranged from 13.00 to 44.11. According to the industry distribution chart, Halozyme Therapeutics ranks #424 out of 537 companies in the Biotechnology industry, placing it in the top 79%.
Is Halozyme Therapeutics' Cyclically Adjusted PS Ratio too high?
Halozyme Therapeutics' current Cyclically Adjusted PS Ratio of 17.54 is 20% below median its 10-year median of 21.94. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 44.11. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.50. Halozyme Therapeutics' value of 17.54 is 218.9% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #424 out of 537 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cyclically Adjusted PS Ratio compare to NUVL and KRYS?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #424 out of 537 companies for Cyclically Adjusted PS Ratio. This places Halozyme Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.50. Halozyme Therapeutics' value of 17.54 is 218.9% above this benchmark. Historically, Halozyme Therapeutics' own Cyclically Adjusted PS Ratio has ranged from 13.00 to 44.11 over the past decade. While the company's 10-year median is 21.94 vs. the industry median of 5.50, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.50, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Cyclically Adjusted PS Ratio of 17.54 is 218.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Cyclically Adjusted PS Ratio is 17.54, which is 20% below median its own 10-year median of 21.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (MIL:1HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is €79.56, compared to a current price of €71.92 — trading 9.6% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 17.54, which is 20% below median its 10-year median of 21.94 and 218.9% above the Biotechnology industry median of 5.50. Halozyme Therapeutics' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (MIL:1HALO), the current Cyclically Adjusted PS Ratio is 17.54 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (MIL:1HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of €71.92 is trading 9.6% below its estimated GF Value™ of €79.56.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for MIL:1HALO:
Cyclically Adjusted PS Ratio: 17.54 (20% below median its 10-year median of 21.94)
GF Value™: €79.56 vs. price of €71.92 (9.6% below fair value)
Industry Position: 218.9% above the Biotechnology median (#424 of 537)
No single metric tells the full story. See the MIL:1HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
75GF Score
Get the complete analysis for MIL:1HALO
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1HALO has been successfully added to your 
